🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The slide we have all been waiting for: OS in #MARIPOSA ▫️OS was significantly improved with amivantamab + lazertinib (HR 0.75) ▫️3 yr OS: 60% with amivantamab + lazertinib v 51% for osimertinib ▫️Curves appear to widen over time Oncology Brothers OncoAlert

Small Cell Lung Cancer 💥Excellent Review👇 jamanetwork.com/journals/jama/…

🚨 Can ctDNA Clearance Predict Response to Neoadjuvant Immunotherapy? 🧬🩸 Valenza et al., Annals of Oncology, 2025 📊 Systematic Review & Meta-analysis | 13 Trials | 380 Patients 🔍 Key Findings: ✅ Sensitivity of ctDNA clearance for predicting pathologic complete response

🫁 Stage III NSCLC 🫁 🫁 ASCO Guideline Rapid Recommendation Update Clinical Insights

🧠Recently published in Neuro-Oncology: Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. Full article 👉doi.org/10.1093/neuonc… #EANOessentails #NeuroOncology #immunotherapy #glioma

Great talk yesterday with over 350 attendees! Thanks to all the moderators and speakers for the brilliant success!

Fino a domani ospiteremo il meeting dell’EORTC Lung Cancer Group: appuntamento strategico per rafforzare la rete europea della ricerca contro il tumore del polmone, che causa oltre 35.000 decessi ogni anno in Italia. Focus su ricerca, innovazione e nuove cure. Marco Tagliamento

Parte oggi il Convegno “Cancer Research: from Chicago to Bari”. Il Presidente #AIOM Perrone: “Il ‘fattore tempo’ è cruciale nella cura del #cancro e siamo preoccupati per i ritardi nell’accesso alle nuove terapie in alcune aree del Paese”. L’articolo: medinews.it/comunicati/tum…

Nuovo trial clinico multicentrico italiano per pazienti affetti da #meningioma SNO EANO AIOM International Consortium on Meningiomas (ICOM) Meningioma UK Meningioma

Special Issue on primary brain tumors!! Unraveling the Molecular Landscape of Primary Brain Tumors mdpi.com/si/241381 #mdpiijms via IJMS MDPI

Heading to Chicago - truly honoured to see the REGOMA-2 study recognized at #ASCO25 Lombardi Giuseppe Thanks Conquer Cancer, the ASCO Foundation

📢ESOncology masterclass for young investigators! 🎥Contents soon available online + submit a study proposal by July 6!💡 We will discuss live on Sept 25 the 4 selected! 👉e-eso.net/courses/25CC9#… Matteo Lambertini, MD PhD Evandro de Azambuja, MD, PhD Benjamin Besse Antonio Marra Saskia Litiere OncoAlert

Join us at #ASCO25 tomorrow to discuss the efficacy of immune checkpoint inhibitors in patients with CNS metastases from solid tumors, a group often overlooked in clinical trials Soraia Lobo-Martins Diogo Martins Branco Evandro de Azambuja, MD, PhD Marco Tagliamento Elisa Agostinetto Eva Blondeaux Matteo Lambertini, MD PhD

Dr. Luis Paz-Ares at #ASCO25 with phase III IMforte trial. Adding maintenance lurbinectidin to first-line maintenance atezolizumab in ES #SCLC improves both PFS & OS, meeting primary endpoints. PFS HR 0.54 and OS HR 0.73 with use of lurbinectedin. Value in avoiding attrition.

Da oggi al 14 con AIOM Fondazione Aiom Fondazione AIRC per la ricerca sul cancro SIRM saremo al Porto Antico del COMUNE DI GENOVA per parlare di #prevenzione in oncologia in occasione dell'arrivo del Tour Vespucci Lucia Del Mastro Matteo Lambertini, MD PhD Carlo Genova Francesca Poggio Davide Soldato Andrea Boutros Università di Genova

Onorata di intervenire a #ESCCardioOnco2025 La collaborazione tra diversi specialisti è un esempio concreto di quanto la multidisciplinarietà sia cruciale nella cura del cancro European Society of Cardiology AIOM #cardiooncology #collaborazione #oncologia #cardiologia #INSIEME

23ª Conferenza Nazionale AIOM: oncologi, associazioni pazienti e metodologi INSIEME per linee guida condivise e centrate sul paziente. Orgogliosi del contributo dell’oncologia genovese Università di Genova Ospedale San Martino Genova: linee guida carcinoma della prostata e preservazione della fertilità

🌓Yin&Yang Masterclass 2025 1st edition comes to an end. Huge thanks to all young and early-career investigators for stepping up, and to the stellar faculty for guiding them with passion and vision. Next stop: Paris 2026 🇨🇵 Stay tuned! #YinYang2025 Mihaela Aldea Biagio Ricciuti, MD, PhD

Datopotamab deruxtecan is now FDA approved for EGFR-mutant #NSCLC after prior EGFR & platinum therapy. In this episode of #LungCancerConsidered, Narjust Florez, MD, FASCO and Jacob sands break down the data and clinical implications of this exciting development. 🎧

🔥🚨Hot Off the Press #BigNews Press Release by AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in